TPWA
BMRN icon

Twin Peaks Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-204
Closed -$11.5K – 486
2026
Q1 		$11.5K Buy
+204
New +$11.9K ﹤0.01% 987
2025
Q3 		– Sell
-229
Closed -$13K – 419
2025
Q2 		$13K Buy
+229
New +$13.5K ﹤0.01% 796

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Twin Peaks Wealth Advisors's BMRN Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 204 shares — an estimated $11.5K sold.

Twin Peaks Wealth Advisors first reported a position in BMRN in Q2 2025 and held it in 2 quarters. The position peaked at $13K in Q2 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 204 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $11.5K.
  • Twin Peaks Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's BioMarin Pharmaceuticals position peaked at $13K in Q2 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.